Andrea wang gillam
CMO Jacobio Pharmaceuticals Inc
Dr. Andrea Wang-Gillam is the Co-CEO, CMO and Global Head of R&D at Jacobio. She is in charge of international business development, global clinical operations and partnerships.
An expert in gastrointestinal oncology, Dr. Wang-Gillam has more than twenty years of research experience in clinical and translational oncology. Born into a family of doctors, she is passionate about prospective research into cancer. Prior to joining Jacobio, she was an oncologist, Director of Gastrointestinal Oncology, and Director of the Early Clinical Trial Center at Washington University School of Medicine in St. Louis, U.S., and served as Principal Investigator (PI) in more than 60 clinical trials. She led the NAPOLI-1 Phase III clinical study of irinotecan liposome injection (Onivyde®), which was later approved for commercialisation in the U.S., Europe, and across Asia.
Dr. Wang-Gillam obtained her M.D. and Ph.D. in molecular biology from the University of Arkansas for Medical Sciences, U.S. She has published more than 100 peer-reviewed papers and been the lead author in multiple papers published in international top-tier journals such as The Lancet, The Lancet Oncology, and the Journal of Clinical Oncology.
Seminars
- How do KRAS alleles, co‑mutations, and tumor lineage reshape dependency and escape, and what does that mean for choosing the right combination backbone?
- Which combinations have true cross‑context potential, and which are only effective in specific molecular or tumor‑type settings?
- How should we prioritise combinations that balance biological rationale, toxicity constraints, and real‑world feasibility across heterogeneous patient populations?
